Clearside Biomedical shares down on Q4 miss

This article was originally published here

Clearside Biomedical

Shares in Clearside Biomedical (NSDQ:CLSD) have fallen slightly today after the biopharmaceutical company posted fourth quarter 2018 earnings that missed expectations on Wall Street.

The Alpharetta, Ga.-based company reported research and development costs of approximately $17.5 million with a total net loss of $21.6 million, or 68¢ per share, for the three months ended December 31, seeing R&D costs grow 25.5% while losses grew 31.2% when compared with the same period during the previous year.

Read the whole story on our sister site, Drug Delivery Business News

The post Clearside Biomedical shares down on Q4 miss appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply